{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:44:11Z","timestamp":1792827851052,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"33","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Idorsia Pharmaceuticals Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>In this double-blind, randomized study of 345 patients with CCS on background oral antiplatelet therapy, subcutaneous selatogrel (8\u2009mg, n\u2009=\u2009114; or 16\u2009mg, n\u2009=\u2009115) was compared with placebo (n\u2009=\u2009116) (ClinicalTrials.gov: NCT03384966). Platelet aggregation was assessed over 24\u2009h (VerifyNow assay) and 8\u2009h (light transmittance aggregometry; LTA). Pharmacodynamic responders were defined as patients having P2Y12 reaction units (PRU) &amp;lt;100 at 30 min post-dose and lasting \u22653\u2009h. At 30 min post-dose, 89% of patients were responders to selatogrel 8\u2009mg, 90% to selatogrel 16\u2009mg, and 16% to placebo (P\u2009&amp;lt;\u20090.0001). PRU values (mean \u00b1 standard deviation) were 10\u2009\u00b1\u200925 (8\u2009mg), 4\u2009\u00b1\u200910 (16\u2009mg), and 163\u2009\u00b1\u200973 (placebo) at 15 min and remained &amp;lt;100 up to 8\u2009h for both doses, returning to pre-dose or near pre-dose levels by 24\u2009h post-dose. LTA data showed similarly rapid and potent inhibition of platelet aggregation. Selatogrel plasma concentrations peaked \u223c30 min post-dose. Selatogrel was safe and well-tolerated with transient dyspnoea occurring overall in 7% (16\/229) of patients (95% confidence interval: 4\u201311%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Selatogrel was rapidly absorbed following subcutaneous administration in CCS patients, providing prompt, potent, and consistent platelet P2Y12 inhibition sustained for \u22658\u2009h and reversible within 24\u2009h. Further studies of subcutaneous selatogrel are warranted in clinical scenarios where rapid platelet inhibition is desirable.<\/jats:p>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehz807","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T19:25:31Z","timestamp":1572031531000},"page":"3132-3140","source":"Crossref","is-referenced-by-count":69,"title":["Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-6229","authenticated-orcid":false,"given":"Robert F","family":"Storey","sequence":"first","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffiel d, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Gurbel","sequence":"additional","affiliation":[{"name":"Inova Heart and Vascular Institute , Falls Church, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5192-886X","authenticated-orcid":false,"given":"Jurrien","family":"ten Berg","sequence":"additional","affiliation":[{"name":"Department of Cardiologie, St Antonius Hospital , Nieuwegein, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3517-1382","authenticated-orcid":false,"given":"Corine","family":"Bernaud","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd , Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D","family":"Dangas","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mount Sinai Hospital , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-3825","authenticated-orcid":false,"given":"Jean-Marie","family":"Frenoux","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd , Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-1451","authenticated-orcid":false,"given":"Diana A","family":"Gorog","sequence":"additional","affiliation":[{"name":"University of Hertfordshire , Hertfordshire, UK"},{"name":"National Heart & Lung Institute , Imperial College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3059-3383","authenticated-orcid":false,"given":"Abdel","family":"Hmissi","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd , Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kunadian","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Newcastle University , Newcastle, UK"},{"name":"Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundations Trust , Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4413-9736","authenticated-orcid":false,"given":"Stefan K","family":"James","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala Clinical Research Center , Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Tanguay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institut de Cardiologie de Montr\u00e9al, Universit\u00e9 de Montr\u00e9al , Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Tran","sequence":"additional","affiliation":[{"name":"Inova Heart and Vascular Institute , Falls Church, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-7121","authenticated-orcid":false,"given":"Dietmar","family":"Trenk","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen , Bad Krozingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Ufer","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd , Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2713-686X","authenticated-orcid":false,"given":"Pim","family":"Van der Harst","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen , Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2344-7564","authenticated-orcid":false,"given":"Arnoud W J","family":"Van't Hof","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Centre (MUMC) , Maastricht, Netherlands"},{"name":"Department of Cardiology, Zuyderland Medical Centre (ZMC) , Heerlen, Netherlands"},{"name":"Department of Cardiology, Isala Hospital , Zwolle, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine , Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"2022102616385723700_ehz807-B1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/heartjnl-2015-307858","article-title":"Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54","volume":"102","author":"Parker","year":"2016","journal-title":"Heart"},{"key":"2022102616385723700_ehz807-B2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102616385723700_ehz807-B3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102616385723700_ehz807-B4","first-page":"103","article-title":"Dual antiplatelet therapy: appraisal of the ACC\/AHA and ESC focused updates","volume":"72","author":"Capodanno","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102616385723700_ehz807-B5","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz425","article-title":"ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102616385723700_ehz807-B6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2012.01.006","article-title":"Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial","volume":"5","author":"Valgimigli","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102616385723700_ehz807-B7","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"key":"2022102616385723700_ehz807-B8","doi-asserted-by":"crossref","first-page":"9133","DOI":"10.1021\/acs.jmedchem.5b00933","article-title":"R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a novel P2Y12 receptor antagonist with a wider therapeutic window in the rat than clopidogrel","volume":"58","author":"Caroff","year":"2015","journal-title":"J Med Chem"},{"key":"2022102616385723700_ehz807-B9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/jcph.1296","article-title":"Clinical pharmacology of the reversible and potent P2Y12 receptor antagonist ACT-246475 after single subcutaneous administration in healthy male subjects","volume":"59","author":"Juif","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2022102616385723700_ehz807-B10","doi-asserted-by":"crossref","first-page":"e00338.","DOI":"10.1002\/prp2.338","article-title":"The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat","volume":"5","author":"Rey","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"2022102616385723700_ehz807-B11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1160\/TH12-10-0718","article-title":"Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay","volume":"109","author":"Sumaya","year":"2013","journal-title":"Thromb Haemost"},{"key":"2022102616385723700_ehz807-B12","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/01.CIR.98.16.1616","article-title":"Differential effects of glycoprotein IIb\/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: implications for assay methodology and comparison of different antagonists","volume":"98","author":"Storey","year":"1998","journal-title":"Circulation"},{"key":"2022102616385723700_ehz807-B13","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022102616385723700_ehz807-B14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40261-014-0236-8","article-title":"A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial","volume":"34","author":"Baldoni","year":"2014","journal-title":"Clin Drug Investig"},{"key":"2022102616385723700_ehz807-B15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3109\/09537104.2012.736045","article-title":"Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study","volume":"24","author":"N\u00fchrenberg","year":"2013","journal-title":"Platelets"},{"key":"2022102616385723700_ehz807-B16","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","article-title":"Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study","volume":"67","author":"Rollini","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102616385723700_ehz807-B17","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"2022102616385723700_ehz807-B18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcin.2015.10.036","article-title":"Randomized comparison of different thienopyridine loading strategies in patients undergoing elective coronary intervention: the ExcelsiorLOAD trial","volume":"9","author":"Hochholzer","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102616385723700_ehz807-B19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1160\/TH16-02-0102","article-title":"Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction","volume":"116","author":"Thomas","year":"2016","journal-title":"Thromb Haemost"},{"key":"2022102616385723700_ehz807-B20","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022102616385723700_ehz807-B21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment\u2013elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102616385723700_ehz807-B22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1160\/TH15-12-0944","article-title":"P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study","volume":"116","author":"Silvain","year":"2016","journal-title":"Thromb Haemost"},{"key":"2022102616385723700_ehz807-B23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2010.01.062","article-title":"Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel or placebo in the ONSET\/OFFSET study","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022102616385723700_ehz807-B24","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehr231","article-title":"Characterisation of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes","volume":"32","author":"Storey","year":"2011","journal-title":"Eur Heart J"},{"key":"2022102616385723700_ehz807-B25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCINTERVENTIONS.111.964197","article-title":"INNOVATE-PCI Investigators. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial","volume":"5","author":"Welsh","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102616385723700_ehz807-B26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1160\/TH16-12-0958","article-title":"Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study","volume":"117","author":"Parker","year":"2017","journal-title":"Thromb Haemost"},{"key":"2022102616385723700_ehz807-B27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH12-08-0547","article-title":"Why does ticagrelor induce dyspnea?","volume":"108","author":"Cattaneo","year":"2012","journal-title":"Thromb Haemost"},{"key":"2022102616385723700_ehz807-B28","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/33\/3132\/46646481\/eurheartj_41_33_3132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/33\/3132\/46646481\/eurheartj_41_33_3132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T16:39:39Z","timestamp":1666802379000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/33\/3132\/5625727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":28,"journal-issue":{"issue":"33","published-online":{"date-parts":[[2019,11,14]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz807","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2019,11,14]]}}}